Annual Report — Form 10-K — SEA’34
Filing Table of Contents
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 4.39M
2: EX-21.1 Subsidiaries List HTML 37K
3: EX-23.1 Consent of Expert or Counsel HTML 28K
4: EX-23.2 Consent of Expert or Counsel HTML 28K
8: EX-97 Clawback Policy re: Recovery of Erroneously HTML 52K
Awarded Compensation
5: EX-31.1 Certification -- §302 - SOA'02 HTML 34K
6: EX-31.2 Certification -- §302 - SOA'02 HTML 34K
7: EX-32 Certification -- §906 - SOA'02 HTML 33K
10: R1 Document and Entity Information HTML 101K
11: R2 Consolidated Balance Sheets HTML 149K
12: R3 Consolidated Balance Sheets (Parenthetical) HTML 51K
13: R4 Consolidated Statements of Income HTML 132K
14: R5 Consolidated Statements of Income (Parenthetical) HTML 32K
15: R6 Consolidated Statements of Comprehensive Income HTML 53K
16: R7 Consolidated Statements of Stockholders' Equity HTML 161K
17: R8 Consolidated Statements of Cash Flows HTML 162K
18: R9 Insider Trading Arrangements HTML 38K
19: R10 Description of Operations and Summary of HTML 115K
Significant Accounting Policies
20: R11 Net Income Per Share HTML 103K
21: R12 Revenue Recognition HTML 75K
22: R13 License and Collaboration Arrangements HTML 65K
23: R14 Consolidated Entities and Acquisitions HTML 155K
24: R15 Equity and Long-Term Investments and Fair Value HTML 337K
Measurements
25: R16 Capitalized Fees Paid HTML 56K
26: R17 Goodwill and Intangible Assets HTML 85K
27: R18 Balance Sheet Components HTML 86K
28: R19 Stock-Based Compensation HTML 172K
29: R20 Stockholders' Equity HTML 40K
30: R21 Debt HTML 195K
31: R22 Commitments and Contingencies HTML 79K
32: R23 Income Taxes HTML 164K
33: R24 Subsequent Events HTML 34K
34: R25 Description of Operations and Summary of HTML 175K
Significant Accounting Policies (Policies)
35: R26 Description of Operations and Summary of HTML 34K
Significant Accounting Policies (Tables)
36: R27 Net Income Per Share (Tables) HTML 101K
37: R28 Revenue Recognition (Tables) HTML 56K
38: R29 Consolidated Entities and Acquisitions (Tables) HTML 130K
39: R30 Equity and Long-Term Investments and Fair Value HTML 287K
Measurements (Tables)
40: R31 Capitalized Fees Paid (Tables) HTML 52K
41: R32 Goodwill and Intangible Assets (Tables) HTML 77K
42: R33 Balance Sheet Components (Tables) HTML 86K
43: R34 Stock-Based Compensation (Tables) HTML 160K
44: R35 Debt (Tables) HTML 157K
45: R36 Commitments and Contingencies (Tables) HTML 68K
46: R37 Income Taxes (Tables) HTML 156K
47: R38 DESCRIPTION OF OPERATIONS AND SUMMARY OF HTML 76K
SIGNIFICANT ACCOUNTING POLICIES - Description of
Operations (Details)
48: R39 DESCRIPTION OF OPERATIONS AND SUMMARY OF HTML 37K
SIGNIFICANT ACCOUNTING POLICIES - Property and
Equipment (Details)
49: R40 DESCRIPTION OF OPERATIONS AND SUMMARY OF HTML 33K
SIGNIFICANT ACCOUNTING POLICIES - Related Party
Transactions (Details)
50: R41 Net Income Per Share (Details) HTML 44K
51: R42 Net Income Per Share - Basic and Diluted EPS HTML 76K
(Details)
52: R43 NET INCOME PER SHARE - Anti-Dilutive Securities HTML 37K
(Details)
53: R44 REVENUE RECOGNITION - Schedule of net revenue from HTML 53K
collaborative arrangements (Details)
54: R45 Revenue Recognition (Details) HTML 98K
55: R46 LICENSE AND COLLABORATION ARRANGEMENTS - HTML 99K
Additional Information (Details)
56: R47 CONSOLIDATED ENTITIES AND ACQUISITIONS - HTML 119K
Theravance Respiratory Company, LLC (Details)
57: R48 CONSOLIDATED ENTITIES AND ACQUISITIONS - ISP Fund HTML 72K
LP (Details)
58: R49 CONSOLIDATED ENTITIES AND ACQUISITIONS - Entasis HTML 92K
Therapeutics Holdings, Inc. (Details)
59: R50 CONSOLIDATED ENTITIES AND ACQUISITIONS - Schedule HTML 91K
of Recognized Identified Assets Acquired and
Liabilities Assumed (Details)
60: R51 CONSOLIDATED ENTITIES AND ACQUISITIONS - La Jolla HTML 52K
Pharmaceutical Company (Details)
61: R52 CONSOLIDATED ENTITIES AND ACQUISITIONS - Pro Forma HTML 48K
Information (Details)
62: R53 EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE HTML 133K
MEASUREMENTS - Equity Investment in Armata
(Details)
63: R54 EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE HTML 90K
MEASUREMENTS - Summarized Financial Data (Details)
64: R55 EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE HTML 113K
MEASUREMENTS - Equity Investment in InCarda
(Details)
65: R56 EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE HTML 55K
MEASUREMENTS - Equity Investment in ImaginAb
(Details)
66: R57 EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE HTML 59K
MEASUREMENTS - Convertible Promissory Note in Gate
Neurosciences (Details)
67: R58 EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE HTML 49K
MEASUREMENTS - Equity Investment in Nanolive
(Details)
68: R59 EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE HTML 49K
MEASUREMENTS - Available-for-Sale Securities
(Details)
69: R60 EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE HTML 162K
MEASUREMENTS - Schedule of Available-for-Sale
Securities Measured at Fair Value on a Recurring
Basis (Details)
70: R61 CAPITALIZED FEES PAID - Schedule of Capitalized HTML 64K
Fees Paid (Details)
71: R62 Goodwill and Intangible Assets (Additional HTML 77K
Information) (Details)
72: R63 Goodwill and Intangible Assets - Summary of HTML 58K
Accumulated Amortization of Recognized Intangible
Assets (Details)
73: R64 BALANCE SHEET COMPONENTS - Schedule of Inventory, HTML 38K
net (Details)
74: R65 BALANCE SHEET COMPONENTS - Additional Information HTML 34K
(Details)
75: R66 BALANCE SHEET COMPONENTS - Schedule Of Other HTML 51K
Accrued Liabilities (Details)
76: R67 BALANCE SHEET COMPONENTS -Schedule of Other HTML 38K
Long-term Liabilities (Details)
77: R68 STOCK-BASED COMPENSATION - 2012 Plan and ESPP HTML 63K
(Details)
78: R69 STOCK-BASED COMPENSATION - Director Compensation HTML 47K
Program (Details)
79: R70 STOCK-BASED COMPENSATION - Stock-Based HTML 60K
Compensation Expense (Details)
80: R71 STOCK-BASED COMPENSATION - Compensation Awards HTML 127K
(Details)
81: R72 STOCK-BASED COMPENSATION - Valuation Assumptions HTML 43K
(Details)
82: R73 Stockholders' Equity (Details) HTML 41K
83: R74 DEBT - Schedule of Debt (Details) HTML 81K
84: R75 DEBT - Convertible Subordinated Notes (Details) HTML 124K
85: R76 DEBT - Convertible Senior Notes (Details) HTML 184K
86: R77 DEBT - Debt Maturities (Details) HTML 45K
87: R78 COMMITMENTS AND CONTINGENCIES - Additional HTML 42K
Information (Details)
88: R79 COMMITMENTS AND CONTINGENCIES - Schedule of HTML 35K
Components of Least Cost (Details)
89: R80 COMMITMENTS AND CONTINGENCIES - Schedule of HTML 35K
Supplemental Cash Flow Information Related to
Lease (Details)
90: R81 COMMITMENTS AND CONTINGENCIES - Schedule of Future HTML 45K
Minimum Lease Payments (Details)
91: R82 INCOME TAXES - Income tax expense (Details) HTML 51K
92: R83 INCOME TAXES - Reconciliation (Details) HTML 51K
93: R84 INCOME TAXES - Deferred Taxes (Details) HTML 57K
94: R85 INCOME TAXES - Additional Tax Disclosures HTML 56K
(Details)
95: R86 SUBSEQUENT EVENTS - Additional Information HTML 58K
(Details)
97: XML IDEA XML File -- Filing Summary XML 194K
100: XML XBRL Instance -- inva-20231231_htm XML 4.36M
96: EXCEL IDEA Workbook of Financial Report Info XLSX 261K
9: EX-101.SCH XBRL Taxonomy Extension Schema With Embedded XSD 6.62M
Linkbases Document -- inva-20231231
98: JSON XBRL Instance as JSON Data -- MetaLinks 804± 1.29M
99: ZIP XBRL Zipped Folder -- 0000950170-24-023237-xbrl Zip 2.83M
Filing Submission 0000950170-24-023237 – SGML Text
To view the SGML, please refresh this page.
↑Top
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help —
Wed., May 8, 12:03:44.6am ET 
